These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 8936959)

  • 21. Growth parameters, growth hormone (GH) response to clonidine and circulating insulin-like growth factor-I (IGF-I), free thyroxine (FT4) and cortisol concentrations in relation to glycaemic control in children with insulin-dependent diabetes mellitus.
    Soliman AT; Ahmed HI; Asfour MG
    J Trop Pediatr; 1996 Aug; 42(4):228-32. PubMed ID: 8816035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The growth and cardiovascular effects of high dose growth hormone therapy in idiopathic short stature.
    Barton JS; Gardineri HM; Cullen S; Hindmarsh PC; Brook CG; Preece MA
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):619-26. PubMed ID: 7634503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH.
    Kamp GA; Zwinderman AH; Van Doorn J; Hackeng W; Frölich M; Schönau E; Wit JM
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):315-25. PubMed ID: 12201823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal handling of phosphate can predict height velocity during growth hormone therapy for short children.
    Nishiyama S; Ikuta M; Nakamura T; Tomoeda S; Matsuda I
    J Clin Endocrinol Metab; 1992 Apr; 74(4):906-9. PubMed ID: 1548358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endogenous and stimulated GH secretion, urinary GH excretion, and plasma IGF-I and IGF-II levels in prepubertal children with short stature after intrauterine growth retardation. The Dutch Working Group on Growth Hormone.
    de Waal WJ; Hokken-Koelega AC; Stijnen T; de Muinck Keizer-Schrama SM; Drop SL
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):621-30. PubMed ID: 7828352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone treatment of short Chinese children with beta-thalassaemia major without GH deficiency.
    Low LC; Kwan EY; Lim YJ; Lee AC; Tam CF; Lam KS
    Clin Endocrinol (Oxf); 1995 Apr; 42(4):359-63. PubMed ID: 7750189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. French Serono Study Group.
    Rappaport R; Mugnier E; Limoni C; Crosnier H; Czernichow P; Leger J; Limal JM; Rochiccioli P; Soskin S
    J Clin Endocrinol Metab; 1997 Feb; 82(2):452-6. PubMed ID: 9024235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma levels of insulin-like binding protein-2 in prepubertal short children and its diagnostic value in the evaluation of growth hormone deficiency.
    van Doorn J; Ringeling AM; Rikken B; van Buul-Offers SC
    Horm Res; 2001; 55(3):147-54. PubMed ID: 11549877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth hormone secretion and circulating insulin-like growth factor-I (IGF-I) and IGF binding protein-3 concentrations in children with sickle cell disease.
    Soliman AT; el Banna N; alSalmi I; De Silva V; Craig A; Asfour M
    Metabolism; 1997 Nov; 46(11):1241-5. PubMed ID: 9361679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Establishment and validation of predictive model of short term responses to recombinant human growth hormone treatment in prepubertal short stature children with various growth hormone secretary statuses].
    Su Z; Li YH; Ma HM; Chen HS; DU ML; Gu YF
    Zhonghua Er Ke Za Zhi; 2008 Oct; 46(10):757-62. PubMed ID: 19099881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of nightly clonidine administration on growth velocity in short children without growth hormone deficiency: a double-blind, placebo-controlled study.
    Allen DB
    J Pediatr; 1993 Jan; 122(1):32-6. PubMed ID: 8419612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can exaggerated response to a GH provocative test identify patients with partial GH insensitivity syndrome?
    Rakover Y; Silbergeld A; Lavi I; Masalha R; Shlomo IB
    Eur J Endocrinol; 2002 Mar; 146(3):319-23. PubMed ID: 11888837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the growth response of children with growth hormone deficiency according to the peak growth hormone levels in provocation tests.
    Donbaloğlu Z; Singin B; Acar S; Bedel A; Barsal Çetiner E; Aydın Behram B; Parlak M; Tuhan H
    Arch Pediatr; 2023 Nov; 30(8):573-579. PubMed ID: 37802668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency.
    Zenaty D; Garel C; Limoni C; Czernichow P; Léger J
    Clin Endocrinol (Oxf); 2003 May; 58(5):647-52. PubMed ID: 12699449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth deficiency in polytransfused beta-thalassaemia patients is not growth hormone dependent.
    Cavallo L; Gurrado R; Gallo F; Zacchino C; De Mattia D; Tatò L
    Clin Endocrinol (Oxf); 1997 Jun; 46(6):701-6. PubMed ID: 9274700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Twenty-four-hour plasma growth hormone (GH) profiles, urinary GH excretion, and plasma insulin-like growth factor-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation.
    Hokken-Koelega AC; Hackeng WH; Stijnen T; Wit JM; de Muinck Keizer-Schrama SM; Drop SL
    J Clin Endocrinol Metab; 1990 Sep; 71(3):688-95. PubMed ID: 2394775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of the outcome of growth hormone therapy in children with idiopathic short stature. A multivariate discriminant analysis.
    Spagnoli A; Spadoni GL; Cianfarani S; Pasquino AM; Troiani S; Boscherini B
    J Pediatr; 1995 Jun; 126(6):905-9. PubMed ID: 7776093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E; Imperiale E; Boffano GM; Mazza E; Bellone J; Arvat E; Procopio M; Goffi S; Barreca A; Chiabotto P
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A; de Muinck Keizer-Schrama SM; Stijnen T; Jansen M; Otten BJ; Delemarre-van de Waal HA; Vulsma T; Wit JM; Rouwé CW; Reeser HM; Gosen JJ; Rongen-Westerlaken C; Drop SL
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4013-21. PubMed ID: 8923853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.